羔羊胃粘膜提取物中双歧因子生物活性检验

本文介绍了含有生物活性酶和双歧因子的羔羊胃粘膜提取物对肠道双歧杆菌促生长作用的试验.试验结果表明,羔羊胃粘膜提取物对双歧杆菌的生长繁殖有明显的促进作用.     

双歧乐对双歧杆菌增殖的影响

本文介绍了唐山市生物化学制药厂生产的双歧乐活性的检验方法和结果.用含有双歧乐的培养基对双歧杆菌进行了定性、定量观察.其结果表明,唐山市生物化学制药厂生产的双歧乐对双歧杆菌有明显的促进作用;在双歧杆菌制剂的生产、实验过程中,如果添加一定量的双歧乐,不仅可以提高双歧杆菌收率,而且还可以缩短菌种发酵时间.     

双歧杆菌冻干粉发酵工艺的筛选

目的:在双歧杆菌冻干粉生产过程中,通过控制发醇工艺参数,提高发酵所产生的菌株数量。方法:采用正交试验的方法,摸索更好的双歧杆菌发酵工艺参数。结果:最后选择发酵温度为37℃、pH值为6．5、双歧因子添加量为4％为双歧杆菌发酵的最佳工艺参数。结论:通过控制发酵温度,pH值和添加双歧因子可以提高双歧杆菌菌株数量。     

双歧杆菌四联活菌制剂治疗新生儿母乳性黄疸疗效观察

目的观察双歧杆菌活菌制剂治疗新生儿母乳性黄疸的疗效。方法对83例新生儿母乳性黄疸患儿随机分为双歧杆菌治疗组和常规治疗组,常规治疗组采用输液、白蛋白静点,重症采用蓝光治疗;双歧杆菌治疗组在常规治疗方法基础上加用双歧杆菌活菌制剂,并观察两组患儿黄疸消退时间及血清总胆红素水平的变化。结果双歧杆菌治疗组和常规治疗组黄疸消退时间分别为（4.2±2.3）、（5.7±2.7）d,两组比较有显著性差异（P〈0.05）,治疗5d血清总胆红素值分别为（45.8±17.5）、（82.7±32.8）μmol/L,两组比较有显著性差异（P〈0.01）。结论双歧杆菌活菌制剂治疗新生儿母乳性黄疸有显著疗效。     

双歧杆菌四联活菌制剂治疗新生儿母乳性黄疸的疗效

目的观察双歧杆菌活菌制剂治疗新生儿母乳性黄疸的疗效。方法对83例新生儿母乳性黄疸患儿随机分为双歧杆菌治疗组和常规治疗组,常规治疗组采用输液、白蛋白静点,重症采用蓝光治疗;双歧杆菌治疗组在常规治疗方法基础上加用双歧杆菌活菌制剂,并观察两组患儿黄疸消退时间及血清总胆红素水平的变化。结果双歧杆菌治疗组和常规治疗组黄疸消退时间分别为(4.2±2.3)、(5.7±2.7)d,两组比较有显著性差异(P<0.05),治疗5d血清总胆红素值分别为(45.8±17.5)、(82.7±32.8)umol/L,两组比较有显著性差异(P<0.01)。结论双歧杆菌活菌制剂治疗新生儿母乳性黄疸有显著疗效。     

蒙脱石散、双歧三联活菌门诊治疗母乳性黄疸32例疗效观察

目的寻找一种既不影响母乳喂哺,又可以不住院治疗,简便、有效、经济的治疗母乳性黄疸的方法。方法32例患儿全部在不停哺母乳的情况下,口服蒙脱石散、双歧三联菌胶囊。每3天用经皮胆红素仪测胆红素值,并记录。结果3d治愈率达78.1%,10d左右全部治愈。结论蒙脱石散加双歧三联活菌治疗母乳性黄疸是适合门诊和家庭的疗效好、简便、经济的治疗方法。保证了母乳喂养不被中断,不需要住院,值得推广。     

双歧杆菌乳杆菌三联活菌治疗母乳性黄疸疗效观察

目的观察双歧杆菌乳杆菌三联活菌(金双歧)治疗母乳性黄疸的临床疗效。方法将母乳性黄疸患儿80例随机分为观察组和对照组各40例。治疗组口服金双歧治疗,对照组给予酶诱导剂苯巴比妥口服。治疗10d后比较2组疗效。结果观察组总有效率和显效率均高于对照组,差异均有统计学意义(P<0.01)。结论金双歧可促进母乳性黄疸的消退,不影响母乳喂养,值得推广应用。     

肠内营养加入双歧因子及双歧杆菌对烫伤大鼠机体免疫力及炎症反应的影响

肠内营养进步之一就是20世纪90年代提出的免疫型、微生态型等新型肠内营养,目的更能有效地改善机体及细胞免疫功能和氮平衡状态,促进创口愈合,降低感染发生率,增强肠道屏障功能。而近年来国内外对双歧杆菌及双歧因子的研究表明,双歧杆菌及其他因子对保持肠道正常微生物菌群平衡及肠黏膜屏障,增强机体非特异和特异性免疫反应,控制内毒血症等方面具有重要作用。本实验目的为探讨双歧因子及双歧杆菌对烫伤大鼠免疫功能及肠黏膜保护作用,对比研     

双歧杆菌及母乳联合应用治疗早产儿喂养不耐受的临床探讨

目的:分析双歧杆菌联合母乳治疗早产儿喂养不耐受效果。方法:选取从2014年1月~2016年1月收治的90例早产儿喂养不耐受,随机分为对照组(45例)与观察组(45例),对照组给予早产儿配方奶喂养,观察组采用双歧杆菌联合母乳喂养,对比两组治疗效果。结果:观察组腹胀消失时间、呕吐消失时间、恢复出生体重时间以及达全肠内营养时间明显短于对照组(P0.05)。结论:对早产儿喂养不耐受采用双歧杆菌联合母乳治疗,安全有效,效果显著,具有临床应用价值。     

双歧杆菌活菌制剂治疗母乳性黄疸疗效观察

母乳性黄疸(BMJ)是1960年由美国Arias及Gartner等首先报道,其主要特点为新生儿母乳喂养后未结合胆红素升高,临床出现黄疸.BMJ对婴儿脑及肾的危害近年也逐渐被认识.以往,BMJ大多以收入院,停母乳,静脉用药,蓝光治疗为主,这给一些家庭,尤其是母亲带来了很大的心理压力.我科自2005年1月至2006年6月在新生儿科及儿保门诊采用双歧杆菌活菌制剂(金双歧)口服治疗BMJ,取得了满意疗效.     

几丁寡糖和壳寡糖的研究进展

本文简单介绍了几丁寡糖和壳寡糖的制备,并对其在抗肿瘤、抗感染、作为双歧杆菌促生长因子、作为植物调节剂、降血脂等方面的功能及产生机制的研究进展作一综述。     

经阴道三维超声在中隔子宫和不良妊娠预测中的诊断价值分析

目的 观察经阴道三维超声在中隔子宫和不良妊娠预测中的诊断价值.方法 对本院经二维超声诊断为中隔子宫的78例患者进行三维超声检查,观察患者的子宫声像图,并对比两种检测结果中完全中隔子宫、不完全中隔子宫、弓状子宫、双角子宫和宫腔粘连的发生率.结果 三维超声检查结果：完全中隔子宫19例,不完全中隔子宫47例,弓状子宫4例,双角子宫4例和宫腔粘连3例,其与临床诊断结果相符率为98.72％,高于二维超声的82.05％ （P＜0.05）.结论 三维超声在检查过程中可对中隔子宫进行较好的成像,提高诊断准确性,有利于辅助临床诊断.     

四联活菌肠溶胶囊治疗慢性腹泻的疗效研究

目的:临床验证双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗慢性腹泻的疗效及安全性。方法:采用多中心、随机、盲法平行对照研究方法。试验组124例给予双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗,对照组80例给予双歧三联活菌胶囊(含长型双歧杆菌、嗜酸乳杆菌和粪肠球菌)治疗,疗程14d,观察腹泻缓解时间及腹泻伴随症状(腹痛、腹胀、里急后重等)变化。结果:试验组3d时腹泻缓解率为41.13%,优于对照组的11.25%(P<0.05);疗程结束时试验组腹泻缓解率为90.32%,大便成形率为75.81%,腹泻伴随症状明显下降,与对照组比较有显著性差异(P<0.05)。结论:双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗慢性腹泻安全、有效。     

新生儿窒息对肠道菌群及体液免疫的影响

目的探讨新生儿窒息对肠道菌群及机体体液免疫的影响。方法选取26例新生儿窒息患儿及26例正常新生儿作为研究对象,分别于生后24～48h对其血清IgA、IgG和IgM进行检测。同时对其粪便进行培养,检测其双歧杆菌和肠球菌的菌落数量,并分析其与体液免疫之间的相关性。结果新生儿窒息患儿在生后24～48h,其血清IgA、IgM水平与正常新生儿相比均存在一定程度的降低。粪便培养结果显示,新生儿窒息患儿粪便中双歧杆菌和肠球菌所形成的菌落数量均较正常新生儿明显减少,并且其菌落数量与血清IgA、IgM水平之间呈明显的正相关。结论新生儿窒息造成了肠道菌群的定植的延缓,进而使机体的体液免疫产生了抑制作用。     

Protein binding of mercury in milk and plasma from mice and man--a comparison between methylmercury and inorganic mercury.

Inorganic mercury has previously been shown to be excreted to milk from plasma to a higher extent than methylmercury. Protein binding of mercury as methylmercury and inorganic mercury in whey and plasma from mouse and man was studied in order to get a better understanding of the transport of mercury into milk. Mice were administered a single i.v. dose of 0.25 mg Hg/kg body weight labelled with (CH3)203HgCl or 203HgCl2, resulting in 11 ng Hg/g milk and 38 ng Hg/g milk after 1 h, respectively. Milk and plasma from mice and man were also incubated with the respective radiolabelled compound (150 ng Hg/g milk or plasma). Casein, fat and whey fractions in milk from methylmercury treated mice were found to contain 11, 39 and 34%, respectively, and from inorganic mercury treated mice 31, 15 and 41%, respectively, of the total amount of mercury in milk. Serum albumin was a major mercury binding protein in whey and plasma from mice for both methylmercury and inorganic mercury, as demonstrated by FPLC gel filtration and anion-exchange chromatography and further characterised by SDS-PAGE for whey. In addition, anion-exchange chromatography indicated that inorganic mercury, but not methylmercury, in whey from mouse milk formed a dimer of serum albumin. The unbound fraction of mercury in whey and plasma from mice was very small (<0.7%), and somewhat higher in plasma and whey from man. It is concluded, that the unbound fraction in plasma cannot be a determining factor for the observed differences in milk excretion between the two mercury compounds. Instead, it is suggested that methylmercury and to some extent inorganic mercury are transferred from plasma into milk using albumin as a passive carrier.     

Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk

AIMS: To assess the effects of pseudoephedrine on breast blood flow, temperature and milk production, and to estimate the likely infant dose during breastfeeding. METHODS: Eight lactating women (mean age 35 years and weight 69 kg) participated in a single-blind randomized crossover study of 60 mg pseudoephedrine hydrochloride vs placebo. Breast blood flow and surface temperature were measured from 0 to 4 h following the dose, and change in plasma prolactin was measured as the difference between predose and 1 h postdose concentrations. Milk production was measured for 24 h following placebo and pseudoephedrine. Infant dose of pseudoephedrine for a 60-mg dose administered four times daily to the mother was quantified as the product of average steady-state drug concentration in milk and an estimated milk production rate of 0.15 l x kg(-1) x day(-1) and expressed relative to the maternal weight-adjusted dose. RESULTS: There were no physiologically significant changes in breast blood flow or temperature between the placebo and pseudoephedrine periods. The mean change in plasma prolactin was slightly (13.5%), but not significantly lower (t = 1.245, P = 0.253) after pseudoephedrine (1775 mU x l(-1)) compared with placebo (2014 mU x l(-1)). However, the mean milk volume was reduced by 24% from 784 ml x day(-1) in the placebo period to 623 ml x day(-1) in the pseudoephedrine period (difference between means 161 ml x day(-1) (95% CI: 63, 259 ml x day(-1)); t = 3.9, P = 0.006). Assuming maternal intake of 60 mg pseudoephedrine hydrochloride four times daily, the estimated infant dose of pseudoephedrine was 4.3% (95% CI, 3.2, 5.4%) of the weight-adjusted maternal dose. CONCLUSIONS: A single dose of pseudoephedrine significantly reduced milk production. This effect was not attributable to changes in blood flow, but depression of prolactin secretion may be a contributing factor. At the maximum recommended pseudoephedrine doses, the calculated infant dose delivered via milk was < 10% of the maternal dose, and is unlikely to affect the infant adversely. The ability of pseudoephedrine to suppress lactation suggests a novel use for the drug.     

肠道菌群失调对小鼠脾脏的影响

目的：观察小鼠肠道菌群失调对脾重、脾细胞数和脾抗体形成细胞数的影响，为研究肠道菌群失调对机体免疫功能的影响提供组织学依据。方法：采用口服卡那霉素造成小鼠肠道菌群失调的动物模型。测定小鼠肠道双歧杆菌、乳杆菌、肠杆菌和肠球菌的数量；测定小鼠脾脏重量和脾细胞数；通过溶血空斑试验测定小鼠脾抗体形成细胞数（PFC）。结果：实验组小鼠肠道内双歧杆菌、乳杆菌、肠杆菌和肠球菌的数量明显低于对照组（P〈0．01）；脾重量、脾细胞数和脾抗体形成细胞数均较对照组明显减少（P〈0．01或P〈0．05）。结论：肠道菌群失调对小鼠脾脏的量与质均有明显的影响。     

回春生制剂对肺心病病人的治疗作用

本文证明长期应用抗生素的肺心病病人,极易造成菌群失调,而双歧杆菌活茵制剂——回春生对此有较为明显的调节作用,同时对肺心病病人的肝功能及免疫功能也有一定程度的改善。     

Occurrence of aflatoxin M1 in raw milk of five dairy species in Ahvaz,Iran

During November 2007 to December 2008, 311 samples of raw milk from cow, water buffalo, camel, sheep, and goat were collected in the Ahvaz (southwest Iran). All of the samples were analyzed for presence of aflatoxin M1 (AFM1) by competitive ELISA technique. AFM1 was found in 42.1% of the samples by average concentration of 43.3 ± 43.8 ng/kg. The incidence rates of AFM1 in raw cow, water buffalo, camel, sheep, and goat milks were, 78.7%, 38.7%, 12.5%, 37.3%, and 27.1%, respectively. The concentration of AFM1 in all of the samples were lower than Iranian national standard and FDA limit (500 ng/l), but in 36% of raw cow milk, 8% water buffalo milk, 3.9% sheep milk, and 5.7% raw goat milk samples were higher than maximum tolerance limit accepted by European union/Codex Alimentarius Commission (50 ng/l). The results showed that the milk of camel, goat, and sheep is safe respect to AFM1 contamination in this area.